New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2012
10:08 EDTIMMUImmunomedics provides update on subcutaneous injections of Veltuzumab
Immunomedics announced that subcutaneous administration of veltuzumab, as a single agent, demonstrated promising activity in patients with relapsed immune thrombocytopenia, even in more heavily treated patients with the chronic disease, and in patients with chronic lymphocytic leukemia. In a published study, veltuzumab reversed life threatening anemia and thrombocytopenia in a patient with systemic lupus erythematosus who was unresponsive to rituximab. In non-Hodgkin lymphoma patients who had received prior therapies, 4 once-weekly infusions of veltuzumab produced a complete response rate of 25% in a study of 84 patients, even at the low dose of 80 mg/m2 given intravenously.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
08:50 EDTIMMUImmunomedics reports preliminary results from pretargeted imaging study
Subscribe for More Information
December 12, 2014
08:33 EDTIMMUImmunomedics ADC continues to produce 30% PR rate, 70% CBR
Subscribe for More Information
December 10, 2014
07:46 EDTIMMUOppenheimer to hold a conference
25th Annual Healthcare Conference is being held in New York on December 10-11.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use